A new clinical trial, titled "FUSION," is currently recruiting participants to evaluate the efficacy and safety of a treatment called ION363 for individuals with amyotrophic lateral sclerosis (ALS) who carry fused in sarcoma (FUS) mutations. Sponsored by Ionis Pharmaceuticals, Inc., this study aims to assess how well ION363 can improve clinical function and survival in these patients.
The trial began on June 14, 2021, and is expected to continue until March 2028. It is currently in Phase 3, which is a critical stage in the development of new treatments. The study is designed to enroll approximately 95 participants, and it is being conducted at multiple locations across the United States and internationally, including sites in Canada, Europe, and Asia.
To be eligible for this trial, participants must be at least 10 years old and can be of any gender. The study involves a randomized, double-masked design, meaning that neither the participants nor the investigators will know who is receiving the treatment or the placebo during the trial. This helps ensure that the results are unbiased.
Participants will receive either ION363 or a placebo, which is an inactive substance, to compare the effects of the treatment. The primary focus of the study is to observe changes in functional impairment over time, as well as other important health measures related to ALS.
The trial is currently recruiting at several prestigious medical centers, including the University of California San Diego, Stanford University Medical Center, Johns Hopkins University, and many others across the globe. This wide reach allows for a diverse group of participants, which is essential for understanding the treatment's effects.
As the trial progresses, it will provide valuable insights into the potential of ION363 as a treatment option for those living with FUS-ALS. The research community is hopeful that this study will contribute to the ongoing efforts to find effective interventions for ALS, a condition that affects many individuals and their families.
For more information about the trial and how to participate, please follow the link provided.
Comments
No comments yet.